A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease
Sponsor: Bayer
Listed as NCT02625974, this PHASE3 trial focuses on Chagas Disease and remains completed. Sponsored by Bayer, it has been updated 37 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
37 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 32 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Buenos Aires, Argentina , Cochabamba, Bolivia , Corrientes, Argentina , Floridablabca, Colombia , Formosa, Argentina , La Plata, Argentina , La Rioja, Argentina , Mendoza, Argentina , Posadas, Argentina , Punata, Bolivia and 10 more locations